Dachaigh › Aillse a' bhroilleach › Georgia › Atlanta
Sgrùdaidhean clionaigeach Aillse a' bhroilleach ann an Atlanta, GA
Tha 41 sgrùdaidhean airson Aillse a' bhroilleach a’ lorg phàirtichean aig làraichean ann agus timcheall air Atlanta (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A’ fastadhÌre 3
- Atlanta Cancer Care - Northside Hospital, Atlanta
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Atlanta VA Medical Center, Decatur · 6 mìle air falbh
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
A’ fastadhÌre 2
- Winship Cancer Institute, Emory University, Atlanta
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
A’ fastadhÌre 3
- Emory Proton Therapy Center, Atlanta
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
A’ fastadhÌre 3
- Emory University Hospital, Atlanta
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
A’ fastadhÌre 3
- Emory University Winship Cancer Institute, Atlanta
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
A’ fastadhÌre 1
- Emory University School of Medicine - Winship Cancer Institute, Atlanta
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
A’ fastadhÌre 2
- Winship Cancer Institute, Atlanta
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
A’ fastadhÌre 1/2
- Winship Cancer Institute of Emory University, Atlanta
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A’ fastadhÌre 3
- Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
A’ fastadhÌre 2
- Emory University (Data Collection Only), Atlanta
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
A’ fastadhÌre 1/2
- Winship Cancer Institute of Emory University, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
A’ fastadhÌre 1
- Emory University, Atlanta
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
A’ fastadhÌre 2
- Emory University, Atlanta
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A’ fastadhÌre 3
- Winship Cancer Institute of Emory University, Atlanta
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
A’ fastadhÌre 3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Piedmont Hospital, Atlanta
- agus 5 a bharrachd
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
A’ fastadhÌre 1
- Emory University - Winship Cancer Institute, Atlanta
Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya
A’ fastadhFàilte do shaor-thoilich fhallain
- Emory University Hospital/Winship Cancer Institute, Atlanta
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
A’ fastadhÌre 1
- Emory University, Atlanta
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
A’ fastadhÌre 2
- Winship Cancer Institute at Emory University, Atlanta
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
A’ fastadhÌre 2/3
- Northside Hospital, Atlanta
E-Mindfulness Approaches for Living After Breast Cancer
A’ fastadhÌre 3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- agus 2 a bharrachd
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
A’ fastadhÌre 1/2
- Emory University, Atlanta
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Winship Cancer Institute, Emory University, Atlanta
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A’ fastadhÌre 1/2
- Winship Cancer Institute, Emory University, Atlanta
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
A’ fastadhÌre 2
- GSK Investigational Site, Atlanta
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
A’ fastadhÌre 3
- Emory University School of Medicine, Atlanta
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
A’ fastadhFàilte do shaor-thoilich fhallain
- Emory University Hospital/Winship Cancer Institute, Atlanta
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Emory University/Winship Cancer Institute, Atlanta
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
A’ fastadhÌre 2
- Winship Cancer Institute of Emory University, Atlanta
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
A’ fastadhÌre 3
- Emory University Hospital Midtown, Atlanta
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
A’ fastadhÌre 2
- Emory University Winship Cancer Institute, Atlanta
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
A’ fastadhÌre 3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Piedmont Hospital, Atlanta
- agus 5 a bharrachd
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Research Site 111, Atlanta
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
A’ fastadhÌre 1/2
- Emory Winship Cancer Institute, Atlanta
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
A’ fastadhSgrùdadh amharc
- Northside Hospital, Atlanta
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
A’ fastadhÌre 1
- Emory University, Winship Cancer Institute, Atlanta
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
A’ fastadhÌre 1
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- agus 1 a bharrachd
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, Atlanta
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
A’ fastadhÌre 3
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
A’ fastadhSgrùdadh amharc
- Piedmont Cancer Institute, Atlanta
- Emory University - Winship Cancer Institute, Atlanta
Sgrùdaidhean Aillse a' bhroilleach ann am bailtean eile
- New York City, NY136 sgrùdaidhean
- Houston, TX126 sgrùdaidhean
- Boston, MA112 sgrùdaidhean
- Nashville, TN81 sgrùdaidhean
- Los Angeles, CA73 sgrùdaidhean
- Edison, NJ68 sgrùdaidhean
- St. Louis, MO64 sgrùdaidhean
- Queens, NY64 sgrùdaidhean
- Durham, NC64 sgrùdaidhean
- Chicago, IL59 sgrùdaidhean
- Philadelphia, PA56 sgrùdaidhean
- Dallas, TX55 sgrùdaidhean
Sgrùdaidhean eile ann an Atlanta
- Aillse (gach seòrsa)49 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag47 sgrùdaidhean
- Myeloma iomaill42 sgrùdaidhean
- Aillse Prostata33 sgrùdaidhean
- Leukemia myeloid geur31 sgrùdaidhean
- Cancer Ovarian29 sgrùdaidhean
- Aillse colorectal29 sgrùdaidhean
- Ailseachadh nan Sgamhan29 sgrùdaidhean
- Ailse metastatach28 sgrùdaidhean
- Galar Depressive Mòr25 sgrùdaidhean
- Fàilligeadh a' Chridhe25 sgrùdaidhean
- Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil24 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.